Quest Diagnostics Offers a 12% Upside as Stability Meets Undervalued Pricing
By stockpickr AI | March 9, 2026 | 10 min read
Investment Summary
Quest Diagnostics is a stable, cash-generative player within the healthcare sector that appears modestly undervalued based on a conservative DCF analysis.
Investment Recommendation
Buy
Fair Value: $165.50
Current Price: $147.25
Upside/Downside: +12.4%
The DCF analysis indicates an intrinsic value per share of approximately $165, suggesting a modest upside from current levels. The company's dependable cash flows and commitment to shareholder returns provide a attractive risk-reward profile.
Key Metrics
- Market Cap: $16.6B
- P/E Ratio: 16.8x
- Forward P/E: 14.5x
- Revenue Growth (YoY): 3.5%
- Net Margin: 9.2%
- ROE: 17.4%
- Debt/Equity: 0.95
- Dividend Yield: 2.1%
Strengths
- Market leadership with a vast footprint of patient access points and clinical laboratory capacity.
- Strong free cash flow generation exceeding $900 million annually, supporting consistent dividend growth.
- Successful execution of the 'Accelerate' strategy, targeting cost efficiencies and revenue-led growth.
- Robust integration of recent strategic acquisitions, such as select hospital system lab outreach businesses.
Risk Factors
- Exposure to potential Medicare and Medicaid reimbursement cuts which could compress margins.
- High labor costs impacting the operating margin as supply chain and staffing shortages persist.
- Intense competition from rival laboratory operators like LabCorp and hospital-owned labs.